Expression of p53 N-terminal isoforms in Bcell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles

TP53 mutations occur in only about 3% of primary and 10–20% of relapse B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). However, alternative mechanisms may contribute to functionally impairing the p53 pathway in the absence of a mutation.